Monitoring Flux in Signalling Pathways Through Measurements of 4EBP1-mediated EIF4F Complex Assembly

Overview

Journal BMC Biol

Publisher Biomed Central

Specialty Biology

Date 2019 May 24

PMID 31118010

Citations 6

Authors

Yuri Frosi

Rachael Usher

Dawn Thean Gek Lian

David P Lane

Christopher J Brown

Affiliations

Soon will be listed here.

Abstract

Background: The most commonly occurring cancer mutations, including oncogenes such as MYC, Ras and PIK3C, are found in signal transductions pathways feeding into the translational machinery. A broad range of translation initiation factors are also commonly found to be either amplified or mis-regulated in tumours, including eIF4E (elongation initiation factor 4E). eIF4E is a subunit of the eIF4F protein initiation complex and required for its recruitment. Here we measure the formation of the eIF4F complex through interactions of eIF4E and eIF4G subunits, and the effect of oncogenic signalling pathways on complex formation.

Results: We developed a protein fragment complementation (PCA) assay that can accurately measure the status of the eIF4E-eIF4G interaction in cells and quantify the signalling flux through the RAS/ERK and PI3K/AKT pathways regulating eIF4F assembly. Complex disruption induced by inhibition of either pathway was shown to be a function of the phosphorylation status of 4EBP1, a key mediator of eIF4F assembly that interacts directly with eIF4E, confirming 4EBP1's ability to integrate multiple signals affecting cap-dependent translation. Maximal measured disruption of the eIF4F complex occurred under combined mTORC1 and mTORC2 inhibition, whilst combined inhibition of both RAS/ERK and PI3K/AKT pathways in parallel resulted in greater inhibition of eIF4F formation than individually. v-Myc-mediated resistance to dual mTORC/PI3K inhibition was also principally demonstrated to depend on the lack of competent 4EBP1 available in the cell to bind eIF4E.

Conclusions: We show that 4EBP1 is a critical regulator of the mitogen responsive RAS/ERK and PI3K/AKT pathways and a key transducer of resistance mechanisms that affect small molecule inhibition of these pathways, principally by attenuating their effects on cap-dependent translation. These findings highlight the importance of highly efficacious direct inhibitors of eIF4E and eIF4F assembly, which could potentially target a wide spectrum of tumours containing differing mutations that effect these pathways and which confer chemo-resistance.

Citing Articles

Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells.

Lum M, Jonas K, Parmar S, Black A, OConnor C, Dobersch S J Clin Invest. 2025; 135(4).

PMID: 39869680 PMC: 11827888. DOI: 10.1172/JCI176093.

Mechanism underlying follicular hyperproliferation and oncogenesis in hidradenitis suppurativa.

Jin L, Kashyap M, Chen Y, Khan J, Guo Y, Chen J iScience. 2023; 26(6):106896.

PMID: 37332597 PMC: 10275975. DOI: 10.1016/j.isci.2023.106896.

Engineering an autonomous VH domain to modulate intracellular pathways and to interrogate the eIF4F complex.

Frosi Y, Lin Y, Shimin J, Ramlan S, Hew K, Engman A Nat Commun. 2022; 13(1):4854.

PMID: 35982046 PMC: 9388512. DOI: 10.1038/s41467-022-32463-1.

Development of a novel peptide aptamer that interacts with the eIF4E capped-mRNA binding site using peptide epitope linker evolution (PELE).

Frosi Y, Ng S, Lin Y, Jiang S, Ramlan S, Lama D RSC Chem Biol. 2022; 3(7):916-930.

PMID: 35866173 PMC: 9257606. DOI: 10.1039/d2cb00099g.

Functional display of bioactive peptides on the vGFP scaffold.

Chee S, Wongsantichon J, Yi L, Sana B, Frosi Y, Robinson R Sci Rep. 2021; 11(1):10127.

PMID: 33980885 PMC: 8115314. DOI: 10.1038/s41598-021-89421-y.

References

Hsieh A, Truitt M, Ruggero D . Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer. 2011; 105(3):329-36. PMC: 3172900. DOI: 10.1038/bjc.2011.241. View

Chen X, Kopecky D, Mihalic J, Jeffries S, Min X, Heath J . Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction. J Med Chem. 2012; 55(8):3837-51. DOI: 10.1021/jm300037x. View

Lama D, Quah S, Verma C, Lakshminarayanan R, Beuerman R, Lane D . Rational optimization of conformational effects induced by hydrocarbon staples in peptides and their binding interfaces. Sci Rep. 2013; 3:3451. PMC: 6506440. DOI: 10.1038/srep03451. View

Ilic N, Utermark T, Widlund H, Roberts T . PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A. 2011; 108(37):E699-708. PMC: 3174675. DOI: 10.1073/pnas.1108237108. View

Soukarieh F, Nowicki M, Bastide A, Poyry T, Jones C, Dudek K . Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation. Eur J Med Chem. 2016; 124:200-217. PMC: 5111791. DOI: 10.1016/j.ejmech.2016.08.047. View

Cardote T, Ciulli A . Cyclic and Macrocyclic Peptides as Chemical Tools To Recognise Protein Surfaces and Probe Protein-Protein Interactions. ChemMedChem. 2015; 11(8):787-94. PMC: 4848765. DOI: 10.1002/cmdc.201500450. View

Janku F, Yap T, Meric-Bernstam F . Targeting the PI3K pathway in cancer: are we making headway?. Nat Rev Clin Oncol. 2018; 15(5):273-291. DOI: 10.1038/nrclinonc.2018.28. View

Choo A, Yoon S, Kim S, Roux P, Blenis J . Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A. 2008; 105(45):17414-9. PMC: 2582304. DOI: 10.1073/pnas.0809136105. View

Muller D, Lasfargues C, El Khawand S, Alard A, Schneider R, Bousquet C . 4E-BP restrains eIF4E phosphorylation. Translation (Austin). 2016; 1(2):e25819. PMC: 4718053. DOI: 10.4161/trla.25819. View

10.

Cencic R, Hall D, Robert F, Du Y, Min J, Li L . Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A. 2010; 108(3):1046-51. PMC: 3024666. DOI: 10.1073/pnas.1011477108. View

11.

Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G . eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014; 513(7516):105-9. DOI: 10.1038/nature13572. View

12.

Igreja C, Peter D, Weiler C, Izaurralde E . 4E-BPs require non-canonical 4E-binding motifs and a lateral surface of eIF4E to repress translation. Nat Commun. 2014; 5:4790. PMC: 4164784. DOI: 10.1038/ncomms5790. View

13.

Scheper G, Proud C . Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation?. Eur J Biochem. 2002; 269(22):5350-9. PMC: 7163980. DOI: 10.1046/j.1432-1033.2002.03291.x. View

14.

Shaw R, Cantley L . Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441(7092):424-30. DOI: 10.1038/nature04869. View

15.

Thean D, Ebo J, Luxton T, Lee X, Yuen T, Ferrer F . Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery. Sci Rep. 2017; 7(1):1763. PMC: 5431883. DOI: 10.1038/s41598-017-01712-5. View

16.

Brown C, Lim J, Leonard T, Lim H, Chia C, Verma C . Stabilizing the eIF4G1 α-helix increases its binding affinity with eIF4E: implications for peptidomimetic design strategies. J Mol Biol. 2010; 405(3):736-53. DOI: 10.1016/j.jmb.2010.10.045. View

17.

McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

18.

Lee C, Reddy E . The v-myc oncogene. Oncogene. 1999; 18(19):2997-3003. DOI: 10.1038/sj.onc.1202786. View

19.

Dowling R, Topisirovic I, Fonseca B, Sonenberg N . Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2009; 1804(3):433-9. DOI: 10.1016/j.bbapap.2009.12.001. View

20.

Gingras A, Raught B, Gygi S, Niedzwiecka A, Miron M, Burley S . Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001; 15(21):2852-64. PMC: 312813. DOI: 10.1101/gad.912401. View